Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price ...
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...
bovnews2d
AKBA’s Latest Twist: What’s Fueling the Unexpected Shifts in Akebia Therapeutics Inc’s Stock Price?
BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...
Akebia Q3 2024 Earnings Preview
Akebia (NASDAQ:AKBA) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open. The ...
Akebia Therapeutics Prepares for Vafseo Launch
Akebia Therapeutics ( (AKBA) ) has released its Q3 earnings. Here is a breakdown of the information Akebia Therapeutics presented to its ...
bovnews5d
Why Did Akebia Therapeutics Inc (AKBA) Stock Surge 14.79% Last Week?
BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...
Morningstar7d
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...
Zacks.com on MSN7d
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures ...
Akebia Therapeutics: Q3 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $20 million in its third quarter. The Cambridge, Massachusetts-based company said it had ...
The Victoria Advocate7d
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Butler, Chief Executive Officer of Akebia. "We expect to enter into contracts with additional dialysis providers to increase coverage over the remainder of 2024 while continuing our efforts to ...
WTOP News7d
Akebia Therapeutics: Q3 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $20 million in its third quarter. The Cambridge, Massachusetts-based company said ...